

# Konstantinos Chiotis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5114300/publications.pdf>

Version: 2024-02-01

42  
papers

2,580  
citations

318942

23  
h-index

325983

40  
g-index

45  
all docs

45  
docs citations

45  
times ranked

4249  
citing authors

#	ARTICLE	IF	CITATIONS
1	[18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5875-5887.	4.1	14
2	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2086-2096.	3.3	11
3	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	3.3	22
4	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 103-117.	1.2	4
5	Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. <i>Molecular Psychiatry</i> , 2021, 26, 5888-5898.	4.1	52
6	Alzheimer's disease spectrum profiled by CSF and imaging biomarkers: Tau PET best predicts cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
7	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. <i>Brain Connectivity</i> , 2020, 10, 555-565.	0.8	18
8	Alzheimer's disease biomarker roadmap 2020: [ 18 F]flortaucipir. <i>Alzheimer's and Dementia</i> , 2020, 16, e039550.	0.4	0
9	Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039556.	0.4	1
10	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557.	0.4	2
11	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.4	3
12	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , 2020, 2, fcaa192.	1.5	24
13	Spatial Normalization of <sup>18</sup> F-Flutemetamol PET Images Using an Adaptive Principal-Component Template. <i>Journal of Nuclear Medicine</i> , 2019, 60, 285-291.	2.8	40
14	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [18F]THK5317 PET. <i>NeuroImage: Clinical</i> , 2019, 22, 101681.	1.4	2
15	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1369-1382.	3.3	74
16	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1276-1286.	3.3	38
17	P4599: ANTE-MORTEM BINDING OF <sup>18</sup> F-THK5317 PET IN A CASE OF FTLD AND POST-MORTEM COMPARISON OF TAU BINDING USING <sup>3</sup> H-THK5117 AND <sup>3</sup> H-MK6240. <i>Alzheimer's and Dementia</i> , 2019, 15, P1554.		0
18	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163.	3.3	30

#	ARTICLE	IF	CITATIONS
19	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.	4.1	409
20	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 348-356.	3.3	41
21	Tau positron emission tomography imaging in tauopathies: The added hurdle of offâ€”target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 232-236.	1.2	86
22	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. , 2018, 14, 652-663.		18
23	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimerâ€™s disease dementia. <i>Molecular Psychiatry</i> , 2018, 23, 1666-1673.	4.1	88
24	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PIB-PET images and correlation with CSF concentrations of A $\beta$ species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	1.4	11
25	Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1605-1617.	3.3	36
26	Comparability of [ <sup>18</sup> F]THK5317 and [ <sup>11</sup> C]PIB blood flow proxy images with [ <sup>18</sup> F]FDG positron emission tomography in Alzheimerâ€™s disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 740-749.	2.4	46
27	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , 2017, 12, 19.	4.4	220
28	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 214-227.	1.5	67
29	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimerâ€™s Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 603-614.	1.2	48
30	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464
31	[P2â€”366]: HEADâ€”TOâ€”HEAD <i>IN VIVO</i> COMPARISON OF TAUâ€”SPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [ <sup>11</sup> C]THK5351 VERSUS [ <sup>11</sup> C]PBB3 PET IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P765.	0.4	1
32	Improved concordance between [11C]PIB PET and CSF A $\beta$ 42 using A $\beta$ 42/A $\beta$ 40: findings from a multicentre European memory clinic population. <i>Neurobiology of Aging</i> , 2016, 39, S18.	1.5	1
33	Comparison of Early-Phase (S)-[18F]THK5117 and [11C]PIB PET imaging to assess brain perfusion in Alzheimerâ€™s disease. <i>Neurobiology of Aging</i> , 2016, 39, S21.	1.5	0
34	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta$ 2 in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
35	Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 38.	3.0	48
36	Tracer Kinetic Analysis of ( <i>S</i> )-[ <sup>18</sup> F]-THK5117 as a PET Tracer for Assessing Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2016, 57, 574-581.	2.8	51

#	ARTICLE	IF	CITATIONS
37	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 922-936.	3.7	235
38	Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1686-1699.	3.3	114
39	Comparison of Early-Phase <sup>11</sup> C-Deuterium-l-Deprenyl and <sup>11</sup> C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1071-1077.	2.8	63
40	Concordance and Diagnostic Accuracy of [ <sup>11</sup> C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1077-1088.	1.2	38
41	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1492-1506.	3.3	11
42	Role of Anthropometric Characteristics in Idiopathic Carpal Tunnel Syndrome. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013, 94, 737-744.	0.5	32